title: Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
abstract: Dopamine (DA) and somatostatin (SRIF) receptor agonists inhibit growth hormone (GH) secretion by pituitary adenomas. We investigated DA subtype 2 receptor (DR2) and SRIF receptor (sst) subtypes 2 and 5 expression in 25 GH-secreting pituitary adenomas and tested in primary culture the effects on GH and prolactin (PRL) secretion of sst agonists selectively interacting with sst2 (BIM-23120), sst5 (BIM-23206), and sst2 and sst5 (BIM-23244). All adenomas expressed sst2; eight adenomas expressed both sst5 and DR2, eight sst5 but not DR2, and eight DR2 but not sst5. One tissue lacked expression of DR2 and sst5. GH secretion was inhibited by BIM-23120 in all samples, while it was reduced by BIM-23206 only in adenomas not expressing DR2. BIM-23120's inhibitory effects correlated with sst2 and DR2 expression, whereas DR2 expression correlated inversely with BIM-23206 inhibitory effects on GH secretion. In seven mixed GH-/PRL-secreting pituitary adenomas, PRL secretion was inhibited in sst5-expressing tumors by BIM-23206, but not by BIM-23120. BIM-23244 reduced PRL secretion only in adenomas expressing sst2, sst5 and DR2. sst5 and DR2 expression correlated directly with BIM23206 inhibitory effects on PRL secretion. Our results suggest that adenomas expressing DR2 are less likely to respond to clinically available SRIF analogs in terms of GH secretion inhibition. Therefore, drugs interacting also with DR2 might better control secretion of pituitary adenomas.
authors.affiliation: Section of Endocrinology, Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, Via Savonarola 9, 44100 Ferrara, Italy.
authors.forename: M C
authors.initials: MC
authors.lastname: Zatelli
authors.forename: D
authors.initials: D
authors.lastname: Piccin
authors.forename: F
authors.initials: F
authors.lastname: Tagliati
authors.forename: A
authors.initials: A
authors.lastname: Bottoni
authors.forename: M R
authors.initials: MR
authors.lastname: Ambrosio
authors.forename: A
authors.initials: A
authors.lastname: Margutti
authors.forename: M
authors.initials: M
authors.lastname: Scanarini
authors.forename: M
authors.initials: M
authors.lastname: Bondanelli
authors.forename: M D
authors.initials: MD
authors.lastname: Culler
authors.forename: E C
authors.initials: EC
authors.lastname: degli Uberti
mesh_terms: D000172:Acromegaly / Q000378:metabolism; D000328:Adult; D000369:Aged, 80 and over; D018491:Dopamine Agonists; D005260:Female; D049912:Growth Hormone-Secreting Pituitary Adenoma / Q000378:metabolism* / Q000473:pathology; D019382:Human Growth Hormone / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D011388:Prolactin / Q000378:metabolism; D020033:Protein Isoforms / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D011954:Receptors, Dopamine / Q000235:genetics / Q000378:metabolism*; D017481:Receptors, Somatostatin / Q000819:agonists / Q000235:genetics / Q000378:metabolism*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000378:metabolism
chemical_list: D018491:Dopamine Agonists; D020033:Protein Isoforms; D012333:RNA, Messenger; D011954:Receptors, Dopamine; D017481:Receptors, Somatostatin; D019382:Human Growth Hormone; D013004:Somatostatin; C094573:somatostatin receptor 5; D011388:Prolactin; C093733:somatostatin receptor 2